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High-Dose Chemotherapy in the Treatment of Relapsed
Osteosarcoma: An Ita l ian Sarcoma Group Study
By F. Fagioli, M. Aglietta, A. Tienghi, S. Ferrari, A. Brach del Prever, E. Vassallo, A. Palmero, E. Biasin, G. Bacci,
P. Picci, and E. Madon
Purpose: To study the feasibility and activity of two
courses of high-dose chemotherapy (HDCT) in patients
with osteosarcoma in metastatic relapse.
Patients and Methods: Patients with high-grade os-
teosarcoma in metastatic relapse (multiple metastases
or solitary metastasis at intervals of less than 30
months) were eligible for study. High-dose chemother-
apy consisted of carboplatin and etoposide followed by
stem-cell rescue. A second course was planned 4 to 6
weeks after the first. Surgery was performed before or
after HDCT.
Results: Thirty-two patients were enrolled onto the
study. At the end of the treatment, 25 patients were in
complete remission (CR), six were alive with disease
progression, and one died of toxicity. At present, 14
patients are alive with a median survival time of 23
months from study entry: four are in first CR, three are
in second CR, and one is in fourth CR. Six patients are
alive with disease. Eighteen patients (56%) died: 17 of
disease and one of toxicity. Transplantation-related
mortality was 3.1%. The relapse or progression disease
rate was 84.4%. The 3-year overall survival rate is 20%
and the 3-year disease-free survival rate is 12%.
Conclusion: HDCT combined with surgery is feasible
and can induce CR in a large portion of patients. Two
points, however, need to be considered: only patients
who are chemosensitive to induction treatment can ob-
tain CR after HDCT, and the length of remission is short,
because most patients relapse. Thus novel strategies are
needed to maintain the remission status or to treat pa-
tients who do not respond to induction treatment.
J Clin Oncol 20:2150-2156. © 2002 by American
Society of Clinical Oncology.
THE PROGNOSIS OF patients with high-grade osteo-sarcoma has greatly improved over the past 25 years,
with overall survival rates increasing from 15% to 70%.
This improvement is attributed to (1) the effect of preoper-
ative chemotherapy,1-4 (2) the introduction of aggressive
chemotherapy with various combinations of high-dose
methotrexate, doxorubicin, cisplatinum, and ifosfamide,5-8
(3) the identification of the relationship of dose-response
between methotrexate, doxorubicin, cisplatinum, and osteo-
sarcoma cells,9,10 and (4) the recognition of the main
prognostic factor, such as the histologic response to preop-
erative chemotherapy, which might change postoperative
chemotherapy.11,12
The prognosis of patients with osteosarcoma in metastatic
relapse is very poor, with overall survival rates between 0%
and 50% after metastasectomy and aggressive second-line
chemotherapy.13-17 In an attempt to improve survival for
patients in metastatic relapse, the Italian and Scandinavian
Sarcoma Group devised a prospective phase II protocol with
high-dose chemotherapy (HDCT) and peripheral-blood
stem-cell (PBSC) reinfusion.18,19 This approach seems at-
tractive for the pharmacokinetic data available in osteosar-
coma patients,20,21 but the nonhematopoietic toxicity of
methotrexate, doxorubicin, cisplatinum, and ifosf-
amide9,22-24 makes these agents unsuitable for dose escala-
tion in HDCT. For HDCT, we chose carboplatin and
etoposide because of their suitable toxicity profile. Recent
data indicate considerable activity of etoposide against bone
and soft tissue sarcomas when it is administered in a
long-term infusion, taking advantage of the phase specific-
ity of this agent.25,26 Carboplatin has also been shown to
have antitumor activity in osteosarcoma.27-31
PATIENTS AND METHODS
Selection of Patients
Patients with high-grade osteosarcoma in metastatic relapse were
considered eligible for this protocol if they had multiple metastases or
solitary metastasis at intervals of less than 30 months from diagnosis,
were younger than 40 years of age, and had normal hepatic and renal
function, a WBC count greater than 3.0  109/L, and platelets greater
than 100  109/L. Before entering this protocol, patients underwent a
physical examination, a chest computed tomography, and a radionu-
clide bone scan. Careful enumeration and measurement of all meta-
static sites was required. All patients or their legal guardians signed a
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document of informed consent consistent with local institutional review
board guidelines.
Treatment
Mobilization of PBSCs was performed using cyclophosphamide 4
g/m2 (day 1) and etoposide 100 mg/m2 over 1 hour every 12 hours
(days 2, 3, and 4; total dose, 600 mg/m2). Granulocyte colony-
stimulating factor 10 g/kg/d was started 48 hours after chemotherapy.
The CD34 cell number required for two re-infusions was 5  106/kg.
High-dose chemotherapy consisted of a 2-hour infusion of carbopla-
tin 375 mg/m2/d for 4 days and continuous-infusion etoposide 450
mg/m2/d for 4 days. PBSCs were infused 48 hours after the end of
HDCT. The first cycle of HDCT was planned 1 to 2 weeks after
mobilization and the second cycle, 4 to 6 weeks after the first. The
protocol outline is shown in Fig 1.
Granulocyte colony-stimulating factor 5 g/kg/d was administered
from day 1 until the neutrophil count was more than 1  109/L for
3 consecutive days. Patients were nursed in a single room at positive air
pressure and received oral nonabsorbable antibiotics (gentamicin and
nystatin). Pneumocystis carinii prophylaxis was performed with neb-
ulized pentamidine 300 mg every 3 weeks from the first day of HDCT.
The surgical management of the metastatic sites was left to the
discretion of the individual surgeon. However, surgical removal of all
metastatic sites was strongly encouraged.
Toxicity
Extra-hematopoietic toxicity was graded according to the Bearman
score.32
Table 1. Patient Characteristics at Study Entry
Patient
No. Sex Site at Diagnosis First-Line Therapy
Age at Study
Entry (years)
No. of
Relapses
Months
From
Diagnosis Site of Relapse (last)
No. of Lung
Metastases
Mono- or Bilateral
Lung Metastases
1 F Tibia NEO5 14 I 24 Lung 13 Bilateral
2 M Fibula Pilot ISG-SSG I 13 I 22 Lung 2 Monolateral
3 F Fibula Pilot ISG-SSG I 14 I 17 Lung 1 (13 cm) Monolateral
4 M Humerus Pilot ISG-SSG I 12 I 15 Lung 13 Bilateral
5 M Femour Pilot ISG-SSG I 13 I 21 Lung 2 Monolateral
6 F Femour Pilot ISG-SSG I 8 I 22 Lung 2 Monolateral
7 M Femour ISG-SSG I 13 I 12 Lung 5 Bilateral
8 M Tibia ISG-SSG I 13 I 15 Bone  lung 2 Monolateral
9 M Humerus ISG-SSG I 9 I 18 Lung 2 Monolateral
10 M Tibia  fibula NEO5 23 I 52 Lung 4 Monolateral
11 M Tibia ISG-SSG I 12 I 10 Lung 2 Bilateral
12 F Tibia Pilot ISG-SSG I 20 I 23 Lung 2 Bilateral
13 M Femour Pilot ISG-SSG I 16 I 19 Lung 4 Bilateral
14 M Tibia ISG-SSG I 22 I 18 Lung 5 Bilateral
15 M Femour ISG-SSG I 36 I 18 Lung 7 Bilateral
16 M Femour ISG-SSG I 17 I 16 Lung 5 Bilateral
17 M Fibula NEO4 25 I 41 Lung 3 Monolateral
18 M Tibia Pilot ISG-SSG I 26 I 34 Lung 2 Bilateral
19 F First cervical vertebra NEO5 38 I 45 Lung 2 Monolateral
20 M Tibia Pilot ISG-SSG I 21 I 27 Bone  lung 20 Bilateral
21 F Femour ISG-SSG I 21 I 12 Lung  lymph node 1 Monolateral
22 F Femour NEO5 13 II 31 Lung 4 Bilateral
23 F Fibula NEO5 15 II 26 Bone  lung 1 Monolateral
24 F Fibula Pilot ISG-SSG I 16 II 23 Lung 7 Bilateral
25 F Radius NEO4 14 II 35 Bone
26 M Femour ISG-SSG I 15 II 15 Lung 7 Bilateral
27 F Fibula Pilot ISG-SSG I 12 II 31 Lung 3 Bilateral
28 F Humerus NEO5 7 II 49 Lung  lymph node 1 (15 cm) Monolateral
29 F Humerus ISG-SSG I 23 II 21 Lung 2 Bilateral
30 M Tibia NEO5 17 III 39 Lung 3 Monolateral
31 M Femour ISG-SSG I 18 III 32 Lung 1 (paracardiac) Monolateral
32 M Tibia ISG-SSG I 17 III 29 Lung 3 Bilateral
Abbreviations: F, female; M, male; ISG-S G, Italian and Scandinavian Sarcoma Group.
Fig 1. Protocol outline. CE, cyclophosphamide 4,000 mg/m2 (day 1);
etoposide 200 mg/m2/d (days 2, 3, and 4). HDCT: etoposide 1,800 mg/m2
(4 days continuous intravenous infusion), carboplatin 1,500 mg/m2 (4 days).
PBSC rescue at 48 hours after termination of chemotherapy. When possible,
surgery was performed within 3 weeks before CE or 4 to 6 weeks after the
second transplantation.
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Clinical Response
Response of lung metastases was assessed radiologically by com-
puted tomography scan. Isotope bone scans were also performed to
monitor bone metastases.
Definitions of response were as follows: complete remission (CR),
radiologic disappearance of all evidence of metastasis; partial response
(PR), 50% reduction in the tumor diameters at all sites; stable disease
(SD), less than 50% decrease or less than 25% increase in the size of
one or more lesions; and progressive disease (PD), more than 25%
increase in the size of one or more of the metastases.
Statistical Analysis
Survival analysis was carried out using the Kaplan-Meier method.33
Event-free survival was defined as the time from the day of transplan-
tation until disease progression or any other cause of death.
Table 2. Characteristics of Previous Relapses in Patients With More Than One Relapse Before Study Entry
Patient
No.
Time From Diagnosis to
First Relapse (months)
Site of First
Relapse
Therapy for First
Relapse
Time From First to
Second Relapse
(months) Site of Second Relapse
Therapy for
Second Relapse
Time From Second to
Third Relapse (months)
22 26 Lung Surgery 5 Lung
23 19 Bone Surgery 7 Bone  lung
24 20 Lung Surgery 2,5 Lung
25 35 Lung Surgery 42 Bone
26 9 Lung Surgery 6 Lung
27 18 Lung Surgery 13 Lung
28 45 Lymph node Surgery 4 Lung  lymph node
29 14 Lung Surgery 7 Lung
30 30 Bone Surgery 4 Lung Surgery 5
31 24 Lung Surgery 4,5 Lung Surgery 3
32 20 Lung Surgery 6 Lung Surgery 3
Table 3. Outcome of Treatment With Primary and Secondary Surgery, Mobilizing Cycle, and HDCT in All Patients
Patient
No.
Outcome After
Primary Surgery
Disease
Status After
Mobilizing
Cycle
Disease
Status After
HDCT
Status at the End of
Treatment With
Secondary Surgery
Months From End of
Treatment to Relapse
Follow-Up and Months
From Study Entry
1 CR CR CR CR 3 Dead, 15
2 CR CR CR CR 9,5 Dead, 28
3 CR CR CR CR 6 Dead, 10
4 CR CR CR CR 13 Dead, 29
5 CR CR CR CR Alive 1st CR, 36
6 CR CR CR CR 8 Dead, 14
7 PR PR PD PD Dead, 11
8 NA SD PD PD Dead, 12
9 NA SD SD CR Alive 1st CR, 22
10 CR CR CR CR Alive 1st CR, 20
11 NA SD SD CR Alive 1st CR, 7
12 NA SD PD PD Dead, 11
13 NA SD SD CR 5 Alive PD, 26
14 NA SD SD CR 10 Alive 2nd CR, 24
15 NA SD SD CR 4 Dead, 16
16 CR CR CR CR 7 Dead, 18
17 NA PR PR CR 13 Alive PD, 19
18 NA SD SD CR 9,5 Dead, 25
19 CR CR CR CR 8 Dead, 21
20 NA SD PD PD Alive PD, 13
21 PR PR PR CR 3 Dead, 8
22 NA PR PR PD Dead, 13
23 NA SD PD PD Dead, 29
24 NA PR CR CR 13 Dead, 33
25 CR CR CR CR 15 Alive 4th CR, 30
26 PR PR CR CR 6 Alive PD, 25
27 NA SD SD CR 13 Alive 2nd CR, 20
28 CR CR CR CR 5 Alive PD, 17
29 NA SD Dead Dead Dead, 3
30 NA PR CR CR 12 Dead, 39
31 NA PR CR CR 4 Alive PD, 11
32 NA SD SD CR 2 Alive 2nd CR, 8
Abbreviation: NA, not assessable.
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RESULTS
Thirty-two Italian patients (19 male and 13 female) were
enrolled onto this study. At the time of study, median
patient age was 15 years (range, 8 to 38 years). The site of
relapse was mainly the lung. Twenty-one patients were in
first relapse at a median of 20 months (range, 10 to 52
months) from diagnosis. All except one had two or more
mono- or bilateral metastases. Eight patients were in second
relapse at a median of 28.5 months (range, 15 to 77 months),
and three patients were in third relapse at 29, 32, and 39
months from diagnosis (Tables 1 and 2).
Surgery was performed in 14 patients before chemotherapy
(primary surgery). Surgery was complete in 11 of these patients.
After the mobilizing cycle, 29 patients achieved the
required CD34 cell number (median, 12.1  106/kg;
range, 5.52 to 25.5) with a median of two aphereses (range,
one to six). Three patients failed (CD34 0, 1.29, and 2.41
 106/kg) and received only one course of HDCT (in the
first two patients bone marrow was added). Another patient
received only one course because she had veno-occlusive
disease after the first course and died of multiple organ failure.
As of April 1, 2001, 28 patients had undergone two
courses of high-dose carboplatin and etoposide, whereas
four patients had one course, for a total of 60 courses.
A median of 10 days (range, 7 to 14 days) was required
to reach a granulocyte count greater than 0.5  109/L, a
median of 11 days (range, 8 to 16 days) was required to reach
a granulocyte count greater than 1  109/L, a median of 12
days (range, 4 to 30 days) was required to reach a platelet count
greater than 25  109/L, and a median of 15 days (range, 7 to
30 days) was required to reach a platelet count greater than 50
 109/L. The median time for hematologic recovery was
similar (no significant difference) after the first and the second
course of high-dose carboplatin and etoposide.
Severe nonhematologic toxicity, according to the Bear-
man score, was present in only five courses: grade 3
stomatitis was present in four courses and grade 3 hepatic
toxicity was present in one course. There was no significant
difference in nonhematologic toxicity between the first and
the second course of chemotherapy.
As shown in Table 3, 11 of 32 patients were in CR before
HDCT, whereas 21 patients underwent HDCT with evident
disease. After the mobilizing cycle, 11 patients were in CR,
eight were in PR, and 13 had SD. After HDCT, 15 patients
were in CR, three were in PR, eight had SD, five had PD,
and one patient died of toxicity. Four additional CRs were
obtained with HDCT among the eight patients in PR after
induction chemotherapy. None of the 13 patients in SD
entered a remission after HDCT. Surgery was performed in
11 patients after HDCT (secondary surgery) and was defin-
itive in 10 patients. Surgery was not performed in five patients
because of PD and in four patients because of CR. At the end
of treatment, 25 patients were in CR and six had PD.
As of April 1, 2001, 14 patients (43.7%) are alive, with a
median survival time of 20 months from study entry (range,
7 to 36 months): four are in first CR at a median of 21
months (range, 7 to 36 months) from study entry, three are
in second CR at 8, 20, and 24 months, and one is in fourth
CR at 30 months. Six patients are alive with disease at 18
months (range, 11 to 26 months). Eighteen patients (56%)
died: 17 of disease at 16 months from study entry (range, 8
to 39 months) and one of toxicity at 3 months (multiple
organ failure). Transplantation-related mortality was 3.1%.
The relapse or PD rate was 84.4%: 21 patients (65.6%)
relapsed with a median time of 8 months (range, 2 to 15
months) and six patients (18.8%) did not respond to treatment.
The 3-year overall survival rate is 20% (Fig 2) and the
3-year disease-free survival is 12% (Fig 3). The median
follow-up time is 18.5 months (range, 3 to 39 months).
Fig 2. Overall patient survival from the day of CE treatment. , Dead.
Fig 3. Disease-free survival. , Relapse; , disease-free.
2153HIGH-DOSE CHEMOTHERAPY IN RELAPSED OSTEOSARCOMA
139.80.123.48
Information downloaded from jco.ascopubs.org and provided by at UNIVERSITY OTAGO on October 19, 2015 from
Copyright © 2002 American Society of Clinical Oncology. All rights reserved.
DISCUSSION
The outlook for patients with high-grade osteosarcoma in
metastatic relapse remains poor. When the lung is the only
site of the disease recurrence, a surgical approach in which
all metastases are removed has been advocated as poten-
tially curative, with a reported 5-year survival rate from the
first thoracotomy of 23% to 50%.13,34-41 The prognosis of
these patients is correlated with the relapse-free interval
from initial diagnosis, the number and the sites of the
metastases, and the complete metastasectomy.13 Incomplete
surgery or development of bone metastases carries a worse
prognosis, with a 0% 4-year overall survival rate.39
Chemotherapy in the management of metastatic osteosar-
coma has no proven benefit, especially in heavily pretreated
patients.35,40-44 However, a number of regimens have been
reported to have been used in these situations, and the
published data are difficult to analyze.25,45-47 There are but
isolated reports of the use of HDCT in patients with
metastatic osteosarcoma.18,19,27,48,49
In an attempt to improve the survival of patients affected
by high-grade osteosarcoma in metastatic relapse, the Ital-
ian and Scandinavian Sarcoma Group devised a phase II
protocol that consists of high doses of carboplatin and
etoposide and PBSC reinfusion. Each of these agents has
considerable activity against osteosarcoma and a suitable
toxicity profile. Dose-limiting toxicity consists of stomatitis
and diarrhea for high-dose etoposide and neuropathy, neph-
rotoxicity, and hepatic toxicity for high-dose carboplatin.
Toxicity data on double high-dose treatment using carbo-
platin and etoposide are derived from phase I/II studies on
adult germ cell tumors and from one pediatric study on
mixed tumors. In one study, high-dose therapy was a part of
the primary therapy.50 In the other three, high-dose therapy
was a part of salvage therapy, usually after extensive use of
chemotherapy containing platinum.27,51,52
The patients enrolled onto this study do not have a good
prognosis. Twenty-one patients were in first relapse at a
median of 20 months from diagnosis. All of these patients
except one had two or more mono- or bilateral metastases.
Eight patients were in second relapse with bilateral metas-
tases of the lung (five patients), lung and bone (one patient),
lung and lymph nodes (one patient), and bone (one patient).
Three patients were in third relapse.
The first-line therapy is shown in Table 1. The patients in
second or in third relapse received surgery. Therefore, all
patients were heavily pretreated, even though a single
course of cyclophosphamide and etoposide allowed an
adequate collection for two re-infusions. Only three patients
failed to achieve the required number of CD34 cells, and
they received just one course of high-dose carboplatin and
etoposide. During the mobilizing cycle, no patients had PD
and five patients were in PR.
After carboplatin and etoposide administration, trilineage
engraftment was promptly observed in all patients, and there
was no significant difference between the first and the
second course of chemotherapy. Furthermore, our results
showed that a two-drug conditioning regimen containing
carboplatin and etoposide is well tolerated. We observed
severe extra-hematopoietic toxicity in only five courses:
severe stomatitis requiring morphine in four courses and
severe hepatic toxicity in one course (this patient died of
multiorgan failure only 3 months after study entry). After
two cycles of HDCT, five patients were in PD, five were in
PR, and four were in CR. At the end of treatment, with
primary or secondary surgery, there were 25 patients in CR
and six in PD. It is important to note that most of these
patients had received cisplatin in first-line therapy and such
patients may develop resistance to platinum agents. Such
acquired cross-resistance after exposure to cisplatin has
been reported in an osteosarcoma cell line.53 Twenty one
patients (65.6%) relapsed, with a median time of 8 months.
In conclusion, combining surgery with HDCT can render
a large proportion of patients disease-free. The evidence that
patients in PR after induction therapy can reach CR after
HDCT indicates that this procedure may be useful for these
patients. Additional maintenance treatment or completely
novel strategies, such as nonmyeloablative allogeneic trans-
plantation, need to be explored to eliminate minimal resid-
ual disease. For patients in SD after primary treatment,
HDCT seems scarcely efficacious. For these chemoresistant
patients, completely new strategies are warranted.
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